Status:

TERMINATED

Interscalene Block With Liposomal Bupivacaine vs. Interscalene Block With Bupivacaine and Adjuvants

Lead Sponsor:

Wake Forest University Health Sciences

Conditions:

Shoulder Arthroplasty

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

The purpose of this study is to determine whether the use of plain bupivacaine with common adjuvants for interscalene block (ISB) provides non-inferior analgesic results compared to the use of liposom...

Detailed Description

The primary objective of this clinical study is to evaluate the comparative efficacy of interscalene block (ISB) using plain bupivacaine with adjuvants vs. liposomal bupivacaine on mean postoperative ...

Eligibility Criteria

Inclusion

  • All patients undergoing total shoulder arthroplasty (not a reverse)
  • Age ≥ 18 years
  • Ability to understand and the willingness to sign an IRB-approved informed consent document.
  • ASA patient status I-III patients
  • Weight Greater than or equal to 50 kg

Exclusion

  • Contraindications to an interscalene block or phrenic blockade
  • Infection at injection site
  • Pre-existing neurological dysfunction affecting the operative extremity
  • Chronic pain diagnosis or opioid use \>40mg oxycodone daily equivalents or use of long-acting opioids
  • BMI \>40
  • Uncontrolled diabetes (A1c \>8.0)
  • Concurrent painful physical condition requiring analgesic treatment (eg, NSAID or opioid) in the postsurgical period for pain not strictly related to the surgery
  • Contraindications to any pain-control agents planned for surgical or postsurgical use (i.e., bupivacaine, hydromorphone, etc.)
  • Patients who are wards of the state
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to bupivacaine or liposomal bupivacaine.
  • Patients with moderate-severe hepatic or renal impairment

Key Trial Info

Start Date :

March 3 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 25 2022

Estimated Enrollment :

25 Patients enrolled

Trial Details

Trial ID

NCT03845894

Start Date

March 3 2020

End Date

June 25 2022

Last Update

November 13 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Wake Forest University Health Sciences

Winston-Salem, North Carolina, United States, 27157

Interscalene Block With Liposomal Bupivacaine vs. Interscalene Block With Bupivacaine and Adjuvants | DecenTrialz